After intravenous or subcutaneous injection, this product is mainly distributed in the kidney, bone marrow and plasma, degraded by amino acid metabolism, and mainly excreted in urine. When injected subcutaneously, the half-life is 3.5 hours and the clearance rate is 0.5-0.7 ml/min/kg.

This product is a platelet-promoting growth factor produced by genetic recombination technology. It can directly stimulate the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells, induce the maturation and differentiation of megakaryocytes, increase the production of platelets in the body, thereby increasing the platelet count in the blood, while there is no significant change in platelet function. Preclinical studies have shown that after the use of this product in vivo, the mature megakaryocytes are completely normal in ultrastructure, and the morphology, function and lifespan of the generated platelets are also normal.

This product is a platelet-promoting growth factor produced by genetic recombination technology. It can directly stimulate the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells, induce the maturation and differentiation of megakaryocytes, increase the production of platelets in the body, thereby increasing the platelet count in the blood, while there is no significant change in platelet function. Preclinical studies have shown that after the use of this product in vivo, the mature megakaryocytes are completely normal in ultrastructure, and the morphology, function and lifespan of the generated platelets are also normal.

This product is a platelet-promoting growth factor produced by genetic recombination technology. It can directly stimulate the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells, induce the maturation and differentiation of megakaryocytes, increase the production of platelets in the body, thereby increasing the platelet count in the blood, while there is no significant change in platelet function. Preclinical studies have shown that after the use of this product in vivo, the mature megakaryocytes are completely normal in ultrastructure, and the morphology, function and lifespan of the generated platelets are also normal.

This product is a platelet-promoting growth factor produced by genetic recombination technology. It can directly stimulate the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells, induce the maturation and differentiation of megakaryocytes, increase the production of platelets in the body, thereby increasing the platelet count in the blood, while there is no significant change in platelet function. Preclinical studies have shown that after the use of this product in vivo, the mature megakaryocytes are completely normal in ultrastructure, and the morphology, function and lifespan of the generated platelets are also normal.